BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30500144)

  • 1. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test.
    Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D
    J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
    Rebeca T; Giselle P; Litchman GH; Rigel DS
    J Drugs Dermatol; 2019 Oct; 18(10):980-984. PubMed ID: 31584775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions.
    Farberg AS; Glazer AM; White R; Rigel DS
    J Drugs Dermatol; 2017 May; 16(5):428-431. PubMed ID: 28628677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Affecting Dermatologists' Use of a 31-Gene Expression Profiling Test as an Adjunct for Predicting Metastatic Risk in Cutaneous Melanoma.
    Svoboda RM; Glazer AM; Farberg AS; Rigel DS
    J Drugs Dermatol; 2018 May; 17(5):544-547. PubMed ID: 29742186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
    Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM
    JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging.
    Schuitevoerder D; Heath M; Cook RW; Covington KR; Fortino J; Leachman S; Vetto JT
    J Drugs Dermatol; 2018 Feb; 17(2):196-199. PubMed ID: 29462228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
    Litchman GH; Fitzgerald AL; Kurley SJ; Cook RW; Rigel DS
    Curr Med Res Opin; 2020 Aug; 36(8):1295-1300. PubMed ID: 32372702
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical Utility of the 31-Gene Expression Profile Test on the Management of Cutaneous Melanoma by Nurse Practitioners and Physician Assistants.
    Block R; Patterson D; Siegel JJ; Martin B; Quick AP; Hunt J
    J Adv Pract Oncol; 2023 Nov; 14(7):586-596. PubMed ID: 38196667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of a 31-Gene Expression Profile Into Clinical Decision-Making in the Treatment of Cutaneous Melanoma.
    Scott AM; Dale PS; Conforti A; Gibbs JN
    Am Surg; 2020 Nov; 86(11):1561-1564. PubMed ID: 32755379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma.
    Dubin DP; Dinehart SM; Farberg AS
    Am J Clin Dermatol; 2019 Dec; 20(6):763-770. PubMed ID: 31359351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
    Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD
    Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Utility of Dermoscopy and 31-Gene Expression Profiling by Dermatology Providers in Melanoma Management Care.
    Witkowski A; Lee C; Latour E; Vetto J; Ludzik J
    J Drugs Dermatol; 2022 Dec; 21(12):1347-1352. PubMed ID: 36468965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
    Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
    Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study.
    Yamamoto M; Sickle-Santanello B; Beard T; Essner R; Martin B; Bailey CN; Guenther JM
    Curr Med Res Opin; 2023 Mar; 39(3):417-423. PubMed ID: 36617959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing.
    Kashani-Sabet M; Leachman SA; Stein JA; Arbiser JL; Berry EG; Celebi JT; Curiel-Lewandrowski C; Ferris LK; Grant-Kels JM; Grossman D; Kulkarni RP; Marchetti MA; Nelson KC; Polsky D; Seiverling EV; Swetter SM; Tsao H; Verdieck-Devlaeminck A; Wei ML; Bar A; Bartlett EK; Bolognia JL; Bowles TL; Cha KB; Chu EY; Hartman RI; Hawryluk EB; Jampel RM; Karapetyan L; Kheterpal M; Lawson DH; Leming PD; Liebman TN; Ming ME; Sahni D; Savory SA; Shaikh SS; Sober AJ; Sondak VK; Spaccarelli N; Usatine RP; Venna S; Kirkwood JM
    JAMA Dermatol; 2023 May; 159(5):545-553. PubMed ID: 36920356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
    Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
    BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test.
    Ahmed K; Siegel JJ; Morgan-Linnell SK; LiPira K
    Cancer Med; 2023 Jan; 12(2):2008-2015. PubMed ID: 35915969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing Genetic Expression Profiles in Melanoma Prognosis.
    Farberg AS; Glazer AM; Winkelmann RR; Rigel DS
    Dermatol Clin; 2017 Oct; 35(4):545-550. PubMed ID: 28886811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of Skin Cancer Diagnosis by Physician Assistants Compared With Dermatologists in a Large Health Care System.
    Anderson AM; Matsumoto M; Saul MI; Secrest AM; Ferris LK
    JAMA Dermatol; 2018 May; 154(5):569-573. PubMed ID: 29710082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
    Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
    J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.